Skip to main
ANNX

Annexon, Inc (ANNX) Stock Forecast & Price Target

Annexon, Inc (ANNX) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 14%
Sell 14%
Strong Sell 0%

Bulls say

Annexon is well-positioned to capture a significant portion of the market for C1q inhibitors, with their lead programs showing promising results and a strong executive team in place. However, the company faces competition from other approved drugs and concerns about the effectiveness of their lead program, vonaprument. It will be important for Annexon to continue to demonstrate the efficacy of their drugs for various conditions and successfully navigate the competitive landscape in order to realize their potential and provide value for investors.

Bears say

Annexon is a clinical-stage biopharmaceutical company with a promising pipeline of products targeting the classical complement pathway, a well-studied mechanism in autoimmune and neurodegenerative diseases. However, their lead drug for a potential $3B market has a low chance of success in its Phase 3 trial, and there may be challenges in marketing and reimbursement for their products. As a result, there is a negative outlook on Annexon's stock.

Annexon, Inc (ANNX) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 14% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Annexon, Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Annexon, Inc (ANNX) Forecast

Analysts have given Annexon, Inc (ANNX) a Buy based on their latest research and market trends.

According to 7 analysts, Annexon, Inc (ANNX) has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Annexon, Inc (ANNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.